Humoral response after SARS-CoV-2 mRNA vaccine in a cohort of hemodialysis patients and kidney...

Presented By:
Prof. Sébastien Hantz, MD, Ph.D.

Speaker Biography:
Prof Sébastien Hantz is a Senior Medical Virologist in the University Hospital of Limoges, France. He’s the head of the department of infectious serologies. From September 2016, Pr Hantz also hold the position of deputy director of the National Reference Centre for Herpesviruses. He completed his medical studies at the University of Limoges in 2005 after 4 years as resident in medical biology and obtained his Doctor of Medicine diploma about “Experiment on genomic screening of human papillomavirus infections on cervical swabs”. From 2005 to 2009, he specialized in virology. He obtained his PhD degree from the University of Limoges, France, in 2009, for his studies on the “cytomegalovirus resistance to antivirals: from the clinic to the structure”. He held a position of assistant professor in Virology from 2009 to 2020. His fundamental research work takes place in the UMR 1092 INSERM, Resinfit, “molecular supports of resistance and therapeutic innovations”, where he’s responsible for the fundamental research axis “antiviral targets of human cytomegalovirus”. He coordinates 2 education units in the University of Limoges (Master 1 and 2) for the research training. As a member of the national university council (CNU 45-01, 2013-2018), he participated to the recruitment of future assistant professors. His area of expertise concerns herpesviruses (mainly CMV and HSV), human papillomavirus, infections transmitted to the fetus and bacteria responsible of sexual transmitted infections. His contributions to science include also the reviewing of many articles for different journals, the participation to many clinical research projects about CMV infection and resistance to antivirals as associated investigator and to advisory board of a vaccine manufacturer. He was also selected as an expert for different French health agencies (INCa, ANSM, HAS).

Webinar:
Humoral response after SARS-CoV-2 mRNA vaccine in a cohort of hemodialysis patients and kidney transplant recipients

Webinar Abstract:
BACKGROUND Kidney transplant recipients and patients on hemodialysis are immunocompromised populations excluded from vaccine trials. Data are lacking regarding their humoral response to COVID vaccination. METHODS We investigated early serological response after COVID 19 vaccination with Pfizer/BioNTech (BNT162b2) mRNA vaccine in 78 patients undergoing hemodialysis, 74 kidney transplant recipients, and 7 healthy controls. Antibody titers against SARS-CoV-2 were measured at 0, 14, 28, 36 and 58 days after the first injection. RESULTS In controls, antibodies were detected at a positive level (13 AU/ml) at day 14 post-injection, and increased progressively, to peak at day 36 (1082 AU/mL [IQR: 735.0-1662]). Patients undergoing hemodialysis had lower titers that peaked at day 58 (276 AU/mL [IQR 83.4-526.0]. A positive antibody level was detected in only 3 kidney transplant recipients. In hemodialysis patients, age, serum albumin and Kt/V were positively correlated with serological response (p 0.043 and p 0.019 respectively); non responders to HBV vaccine had the lowest titers of anti-SARS-CoV-2 antibodies. CONCLUSIONS Our results suggest that the post-vaccine humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients, while it is lowered by the uremic condition in patients undergoing hemodialysis.

Earn PACE Credits:

LabRoots on Social:
SnapChat: labroots_inc